title: Elevated glucose level at 30 minutes during an oral glucose tolerance test in obese adolescents: a new disorder of glucose tolerance.
abstract: We observed glucose levels >140 mg/dL measured at 30 minutes (min) during an oral glucose tolerance test (OGTT) in some obese patients. We aimed to investigate the significance of this finding by comparing lipid profiles, insulin resistance indices, and systemic inflammatory mediators between obese adolescents with normal glucose tolerance (NGT), impaired glucose tolerance (IGT), and elevated glucose levels at 30 min. The study involved 80 obese (body mass index >95(th) percentile for age and sex) adolescents (48 female, 32 male) between 11 and 16 years of age. Depending on OGTT results, patients were divided into NGT and IGT groups. The third group was recruited from the NGT group as having glucose levels > 140 mg/dL at 30 minutes. Lipid profiles, [interleukin-6 (IL-6)], neopterin, and lipoprotein associated phospholipase A₂ (Lp-PLA₂)] were assessed. Neopterin and Lp-PLA₂ levels were significantly higher in obese adolescents with elevated glucose levels at 30 min. compared with those in both NGT and IGT groups (p=0.013, and 0.004, respectively). In these adolescents, IL-6 levels were significantly higher only than the NGT group (p=0.01). In logistic regression analysis, IL-6, neopterin and Lp-PLA₂ levels were detected to be related to high blood glucose levels at 30 min (OR 1.11, p=0.01; OR 9.03, p=0.013; OR 1.01, p=0.004 respectively). Obese adolescents with elevated glucose levels at 30 min. demonstrated higher inflammatory mediators levels, which were atherosclerotic indicators, than obese adolescents with NGT and IGT. These results suggest that glucose levels >140 mg/dL measured at 30 min during an OGTT may be a new disorder of glucose tolerance in obesity.
authors.affiliation: Department of Clinical Biochemistry, Ege University School of Medicine, İzmir, Turkey.
authors.forename: Ceyda
authors.initials: C
authors.lastname: Kabaroğlu
authors.forename: Betül
authors.initials: B
authors.lastname: Ersoy
authors.forename: Ece
authors.initials: E
authors.lastname: Onur
authors.forename: Bayram
authors.initials: B
authors.lastname: Özhan
authors.forename: Soner
authors.initials: S
authors.lastname: Erdin
authors.forename: Ahmet
authors.initials: A
authors.lastname: Var
authors.forename: Oya
authors.initials: O
authors.lastname: Bayındır
authors.forename: Gönül
authors.initials: G
authors.lastname: Dinç
mesh_terms: D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase / Q000097:blood; D000293:Adolescent; D001786:Blood Glucose / Q000032:analysis; D015992:Body Mass Index; D002648:Child; D005260:Female; D018149:Glucose Intolerance / Q000097:blood / Q000150:complications / Q000175:diagnosis* / Q000276:immunology; D005951:Glucose Tolerance Test; D006801:Humans; D006943:Hyperglycemia / Q000209:etiology*; D018836:Inflammation Mediators / Q000097:blood*; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D015850:Interleukin-6 / Q000097:blood; D016015:Logistic Models; D008297:Male; D019798:Neopterin / Q000097:blood; D009765:Obesity / Q000150:complications*; D014421:Turkey; D015854:Up-Regulation
chemical_list: D001786:Blood Glucose; C508600:IL6 protein, human; D018836:Inflammation Mediators; D007328:Insulin; D015850:Interleukin-6; D019798:Neopterin; D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase